Bridging Adult Experience to Pediatrics in Oncology Drug Development. (15th September 2017)

• Record Type: Journal Article
• Authors: Leong, Ruby; Zhao, Hong; Reaman, Gregory; Liu, Qi; Wang, Yaning; Stewart, Clinton F.; Burckart, Gilbert
• Other Names: Lee Lucy guestEditor.; Lewis Lionel D. guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 57(2017)Supplement 10
• Page Start: S129
• Page End: S135
• Publication Date: 2017-09-15
• Subjects: pediatrics -- oncology -- dosing -- bridging; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.910
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Pediatric drug development in the United States has grown under the current regulations made permanent by the Food and Drug Administration Safety and Innovation Act of 2012. Over 1200 pediatric studies have now been submitted to the US FDA, but there is still a high rate of failure to obtain pediatric labeling for the indication pursued. Pediatric oncology represents special problems in that the disease is most often dissimilar to any cancer found in the adult population. Therefore, the development of drug dosing in pediatric oncology patients represents a special challenge. Potential approaches to pediatric dosing in oncology patients include extrapolation of efficacy from adult studies in those few cases where the disease is similar, inclusion of adolescent patients in adult trials when possible, and bridging the adult dose to the pediatric dose. An analysis of the recommended phase 2 dose for 40 molecularly targeted agents in pediatric patients provides some insight into current practices. Increased knowledge of tumor biology and efforts to identify and validate molecular targets and genetic abnormalities that drive childhood cancers can lead to increased opportunities for precision medicine in the treatment of pediatric cancers.